PRESIDENT’S UPDATE October 2020
It’s been more than a year now since Mylan and Pfizer announced a planned merger between Mylan and Pfizer’s worldwide generic division Upjohn. The deal has been held up pending necessary approvals from numerous countries and it looks like the final hurdle, the United States, could happen before the end of this year.
The new company, which will be known as Viatris, is expected to have worldwide revenues of close to $20 billion which would make it close to the top 10 largest.
The DEA has recently proposed a large decrease in quotas for narcotics next year just as they did this year. As we get closer to the end of the year it is possible that we could start to see manufacturers running out of material to make enough product to meet demand. Keep your eye on your inventory levels so you don’t run out early.
We are out of most SKU’s of levothyroxine from Sandoz but we now have plenty of stock of the same exact product with the Lannett label. We also have Alvogen in stock. Both brands come in the unit-of-use 90 count bottles as well as 1000 counts.
We are expecting several first-time generics before the end of this year. We hope to see generics for Atripla, Chantix, Ofimev, Saphris, Tirosint, and Truvada. Be sure to check with your Auburn Account Manager and AuburnGenerics.com for current information.
And don’t forget to look over the many new short-date and closeout deals available on GenericBid.com! It’s the only website that offers weekly bidding on numerous great products. The savings are up to 90% off and products have 1-12 months expiration dates. Just sign in with your AuburnPharm.com password. Try it out for a fun and easy way to save!